rdfs: label
ar
bs
de
el
en
es
eu
fa
fi
fr
he
hu
id
it
ja
ko
la
mk
nl
or
pl
pt
ro
ru
sh
sl
sr
sr-ec
sr-el
tr
uk
vi
zh
"Nebibolol"@eu
"Nebivolol"@bs
"Nebivolol"@de
"Nebivolol"@es
"Nebivolol"@id
"Nebivolol"@ro
"Nebivolol"@sh
"Nebivolol"@sr-el
"Nebivolol"@tr
"Nebivolol"@vi
"nebivolol"@en
"nebivolol"@hu
"nebivolol"@nl
"nebivolol"@pt
"nebivolol"@sl
"nebivolol"@sr
"nebivololi"@fi
"nebivololo"@it
"nebivololum"@la
"nebiwolol"@pl
"nébivolol"@fr
"Νεμπιβολόλη"@el
"Небиволол"@mk
"Небиволол"@sr-ec
"Небіволол"@uk
"небиволол"@ru
"נביבולול"@he
"نبیوولول"@fa
"نيبيفولول"@ar
"ନେବିଭୋଲୋଲ"@or
"ネビブロール"@ja
"奈必洛爾"@zh
"네비보롤"@ko
skos: altLabel
en
he
ja
"1,1'-[bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)]-2,2'-iminodiethanol"@en
"1,1'-bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-yl)-2,2'-iminodiethanol"@en
"Bystolic"@he
"Nebilet"@he
"R-65824"@en
"Ro-67555"@en
"alpha,alpha'-(iminobismethylene)bis-(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol)"@en
"alpha,alpha'-(iminodimethylene)bis-(6-fluoro-2-chromanmethanol)"@en
"נביוולול"@he
"ネビボロール"@ja
schema: description
af
an
ar
ast
be
be-tarask
bg
bn
br
ca
cs
cy
da
de
de-ch
el
en
en-ca
en-gb
eo
es
et
eu
fi
fr
fy
gcr
gl
he
hy
ia
id
io
it
ko
ks
la
lb
lv
mk
ml
nb
nl
nn
oc
or
pl
pt
pt-br
ro
ru
scn
sk
sq
tr
uk
vec
yue
zh
zh-cn
zh-hans
zh-hant
zh-hk
zh-mo
zh-sg
zh-tw
"Kompozé chimik"@gcr
"cheemesch Verbindung"@lb
"chemical compound"@en
"chemical compound"@en-ca
"chemical compound"@en-gb
"chemická sloučenina"@cs
"chemická zlúčenina"@sk
"chemiese verbinding"@af
"chemische Verbindung"@de
"chemische Verbindung"@de-ch
"chemische verbinding"@nl
"component quimic"@oc
"composito chimic"@ia
"compositum chemicum"@la
"compost químic"@ca
"composto químico"@gl
"composto químico"@pt
"composto químico"@pt-br
"composé chimique"@fr
"compuesto quimico"@an
"compuestu químicu"@ast
"compus chimic"@ro
"conposto chìmego"@vec
"cumpostu chìmicu"@scn
"cyfansoddyn cemegol"@cy
"gemyske ferbining"@fy
"kediad kimiek"@br
"keemiline ühend"@et
"kemia kombinaĵo"@eo
"kemiala kompozajo"@io
"kemiallinen yhdiste"@fi
"kemisk forbindelse"@da
"kimyasal bileşik"@tr
"kjemisk forbindelse"@nb
"kjemisk sambinding"@nn
"komponim kimik"@sq
"konposatu kimiko"@eu
"medicamento beta bloqueador"@es
"principio attivo appartenente alla classe dei betabloccanti cardioselettivi specifici sui recettori β1 adrenergici, e con un effetto vasodilatatore aggiuntivo sulle arterie"@it
"senyawa kimia"@id
"związek chemiczny"@pl
"ķīmisks savienojums"@lv
"χημική ένωση"@el
"хемиско соединение"@mk
"химическое соединение"@ru
"химично съединение"@bg
"хімічна сполука"@uk
"хімічнае злучэнне"@be
"хімічнае злучэньне"@be-tarask
"քիմիական միացություն"@hy
"תרופה ממשפחת חוסמי בטא המשמשת לטיפול ביתר לחץ דם ובאי-ספיקת לב"@he
"مركب كيميائي"@ar
"کیٖمیٲیی مُرَکَب"@ks
"রাসায়নিক যৌগ"@bn
"ଉଚ୍ଚ ରକ୍ତଚାପ ଓ ହୃଦ୍ପାତ ଚିକିତ୍ସାରେ ଦିଆଯାଏ ।"@or
"രാസസംയുക്തം"@ml
"化合物"@yue
"化合物"@zh
"化合物"@zh-cn
"化合物"@zh-hans
"化合物"@zh-hant
"化合物"@zh-hk
"化合物"@zh-sg
"化合物"@zh-tw
"化合物"@zh-mo
"베타 차단제"@ko
schema: dateModified
"2026-11-04T18:37:25+00:00"^^xsd:dateTime
schema: version
2564788419
wikibase: identifiers
35
wikibase: sitelinks
30
wikibase: statements
85
p: P10245
wd: statement/Q418130-4cdc6d5a-4f10-75e1-7e85-62bf675e8c72
p: P10283
wd: statement/Q418130-810A7DD5-C4E1-4E83-BA9B-B16CCBE7582B
p: P11089
wd: statement/Q418130-E0EA8FFC-3C3F-4650-BC0A-CFE72CD0E884
p: P11143
wd: statement/Q418130-592036F8-7BF0-4803-8DB6-C935AC5E1460
p: P11198
wd: statement/Q418130-4B04E49F-90AD-44DE-914B-3B4D725CC897
p: P11199
wd: statement/Q418130-FC29100E-4067-4129-8040-D144DE9D2DD0
p: P117
wd: statement/Q418130-30c6e658-4917-9d5b-f27d-6b3d44a9556c
p: P1579
wd: statement/Q418130-17B4D390-0293-4F2B-8694-E0248FA9FC46
p: P2057
wd: statement/Q418130-4379E3CA-558B-4421-A77C-05F5CC478818
p: P2067
wd: statement/Q418130-CC726CF7-0ED6-4608-94CB-45A059E495AA
p: P2115
wd: statement/Q418130-76CF0CD6-48B8-486B-B04F-00E944696802
p: P2175
wd: statement/Q418130-6D35B47F-3FC5-45C4-B758-714D41D6141F
p: P2275
wd: statement/Q418130-485645BA-BBA1-4602-A54A-75E3E659B179
p: P231
wd: statement/Q418130-DF98190E-37E3-412D-9FC0-514D7226C4E3
p: P233
wd: statement/Q418130-C8843202-56E8-4ECD-8FB8-A67690095B2E
p: P234
wd: statement/Q418130-D582D9C7-E176-44BF-8852-D934C11C892B
p: P235
wd: statement/Q418130-5C3ED9C7-E274-4D7D-9190-AEE09B5A5073
p: P267
wd: statement/Q418130-A7FF054C-070C-41C9-8DCC-C0C36FA0532D
p: P274
wd: statement/Q418130-E416F0E0-FFA0-494E-8BA2-B27454EA5FAF
p: P279
wd: statement/Q418130-C717AEF0-9F9D-4162-A9AD-E2FAA548F414
p: P2868
wd: statement/Q418130-1CCC99C2-FB33-4295-A5F7-A4A600C4C0E6
wd: statement/Q418130-675DA6D0-8843-48C5-AF1F-D52D5E67BDF4
wd: statement/Q418130-6DE1F549-CB73-4A16-BC44-CC22CDA029B4
wd: statement/Q418130-C5A91760-2F45-4699-AF71-D154BBF10C70
p: P2877
wd: statement/Q418130-C3D7DB22-1BAD-49F0-92E5-373FE4F08748
p: P31
wd: statement/Q418130-BBCBD1D8-F1A7-4451-8135-21B587978592
p: P3117
wd: statement/Q418130-D75F306B-0891-4E93-A5B6-0453DBDC368D
p: P3345
wd: statement/Q418130-342F0303-5529-4111-81CF-A9F4393A403F
p: P3417
wd: statement/Q418130-2C9159EC-925E-476A-84C4-C8ECA9ED6C08
p: P3489
wd: statement/Q418130-3D035E15-393A-4DCF-A5EE-045D4C7ACA88
p: P366
wd: statement/Q418130-1A9BBC0B-0F92-45D8-BEBE-DB49D3407AEE
p: P373
wd: statement/Q418130-b8e78cf0-44ff-8f26-ae66-46cb13e8bb2b
p: P4250
wd: statement/Q418130-79C64C9D-95CA-434F-A6F0-95EE13000D13
p: P486
wd: statement/Q418130-96514E1E-3459-486C-B89B-7F6B28271C59
p: P592
wd: statement/Q418130-1B12E3B1-372E-4ADD-8865-8A77B77CC008
p: P595
wd: statement/Q418130-73EC21CE-B25D-4899-B103-C4B360B0FCDD
p: P6366
wd: statement/Q418130-90EB7A77-87C4-409A-87D2-1469FCA9A7FA
p: P646
wd: statement/Q418130-1EF704D4-78EF-4210-A4DC-A15EEC9A22E6
p: P652
wd: statement/Q418130-C124DCBB-2227-46CA-8470-CAFCD5B316F3
p: P661
wd: statement/Q418130-7C35E8BA-3A60-45B9-9AC7-2EBC0F88443A
p: P662
wd: statement/Q418130-E5A809C2-833D-44FB-AFAF-1428CD4B7897
p: P665
wd: statement/Q418130-ECDD8DCC-9BB1-4283-B82F-A0B608758DD3
p: P672
wd: statement/Q418130-40797e3b-487f-0231-2a5d-692dfb991919
wd: statement/Q418130-91c36dea-4cc0-5ffe-5b19-627a2e237d2f
wd: statement/Q418130-ddda9609-4344-1c13-011e-715911135ad9
wd: statement/Q418130-e29bca4a-4e19-d03b-38f1-ca56f8340947
p: P683
wd: statement/Q418130-328F042C-C9B2-4D57-B37E-C9F3FEEAC3B1
p: P715
wd: statement/Q418130-806C7729-25CD-4108-A92B-060FE2F7B77A
p: P769
wd: statement/Q418130-0DB74110-4CD3-4533-801F-8581427C46F7
wd: statement/Q418130-0E40C810-A1A1-4DD2-8919-3F78DCF34110
wd: statement/Q418130-1248F595-576B-4DEA-ABE6-6763B5AC39E3
wd: statement/Q418130-1D637756-777C-4798-AB42-A35F5B982F53
wd: statement/Q418130-40868402-30C2-47F4-BCC9-A9514C54C018
wd: statement/Q418130-42B68986-CF9F-435B-9E69-F88DE77E9825
wd: statement/Q418130-473BC8A0-15EB-41BD-973A-7E3763193808
wd: statement/Q418130-51F0B95C-5C1F-4984-9CDC-42EE42773E14
wd: statement/Q418130-558EFF9F-5D61-499A-AD09-D7AEFB6564D1
wd: statement/Q418130-59235970-4674-4B16-B2D4-B2C1C68FC439
wd: statement/Q418130-6269C0FC-26D8-4823-AFB2-2A28AE5508DE
wd: statement/Q418130-65A828B4-8F64-40DD-A3AE-C04230C112EF
wd: statement/Q418130-69F2BE7D-ADD2-41A1-A011-D0FA0FDE7F07
wd: statement/Q418130-6D74F1DD-E84E-4C51-BC97-3687CC60C3A2
wd: statement/Q418130-78172021-63BE-444B-8A0B-D5FC03832D83
wd: statement/Q418130-78F72F5C-8A1F-48E6-9956-055986EE946D
wd: statement/Q418130-88FEBE66-F655-4F59-BBE9-D31083424B04
wd: statement/Q418130-940D6F90-D6F5-4865-A83C-1EEEC4CD8E3C
wd: statement/Q418130-9B5A8B4F-3B77-4990-90E8-4CBB2ED01665
wd: statement/Q418130-B033A798-8C12-4274-957B-3C8770828DEB
wd: statement/Q418130-B3A19B3F-AD44-4984-BB65-8F9846084810
wd: statement/Q418130-B73E8AB3-D66A-4FD5-8D64-E7B775742B0E
wd: statement/Q418130-BA239CCE-4677-4D6B-A31B-A474788DE0B2
wd: statement/Q418130-BC834548-BCF0-4AB3-A176-0C9BB7F09A3A
wd: statement/Q418130-C3DC160D-CC31-4F28-9751-1D62549CDB78
wd: statement/Q418130-CA4F5008-62DB-4A28-961C-4CA2E70FE809
wd: statement/Q418130-D00A4F53-BC1F-459A-BDF3-3E2EF23F9DE1
wd: statement/Q418130-D94B74D9-E08F-4FF1-ADD7-25FC51DFC9D5
wd: statement/Q418130-E2235662-9C10-4C38-9B08-ACA5EEA4A6CE
wd: statement/Q418130-E8CF8509-7C4F-49A4-A1FA-4C2ABDC22D4F
wd: statement/Q418130-E9F781EE-C763-48B5-B8F4-AA398AC835FA
wd: statement/Q418130-F2BC76E5-B9E3-4259-9629-8C194D2AF304
wd: statement/Q418130-F700FBDC-860E-456F-BB3C-13F0D8754315
p: P7830
wd: statement/Q418130-8F8D95F5-AC36-4479-BEC0-C5C49412D182
p: P8026
wd: statement/Q418130-39FF92FF-564B-4EEE-962D-29F00D0BEA74
p: P8494
wd: statement/Q418130-6DA8E92B-657D-4011-9B95-8B1745E31A92
p: P9272
wd: statement/Q418130-6789C20F-3BFF-4E23-BB5B-E44B8FC399DD
p: direct-normalized/P2115
<http://purl.bioontology.org/ontology/NDFRT/N0000176131>
p: direct-normalized/P486
<http://id.nlm.nih.gov/mesh/D000068577>
p: direct-normalized/P592
<http://rdf.ebi.ac.uk/resource/chembl/molecule/CHEMBL434394>
p: direct-normalized/P6366
<https://makg.org/entity/2777537511>
p: direct-normalized/P661
<http://rdf.chemspider.com/64421>
p: direct-normalized/P662
<http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71301>
p: direct-normalized/P665
<http://www.kegg.jp/entry/D05127>
p: direct-normalized/P672
<http://id.nlm.nih.gov/mesh/D02.033.100.291.491>
<http://id.nlm.nih.gov/mesh/D02.092.063.291.503>
<http://id.nlm.nih.gov/mesh/D03.383.663.283.755>
<http://id.nlm.nih.gov/mesh/D03.633.100.150.755>
p: direct-normalized/P683
<http://purl.obolibrary.org/obo/CHEBI_64019>
wdt: P10245
"a608029"
wdt: P10283
"C2777537511"
wdt: P11089
"51276"
wdt: P11143
"Nebivolol"
wdt: P11198
"1887"
wdt: P11199
"PD009358"
wdt: P117
<http://commons.wikimedia.org/wiki/Special:FilePath/Nebivolol.svg>
wdt: P1579
"8729344"
wdt: P2057
"HMDB0015594"
wdt: P2067
405.175165^^xsd:decimal
wdt: P2115
"N0000176131"
wdt: P2175
arterial hypertension
wdt: P2275
"nebivolol"@en
wdt: P231
"99200-09-6"
wdt: P233
"C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O"
wdt: P234
"InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2"
wdt: P235
"KOHIRBRYDXPAMZ-UHFFFAOYSA-N"
wdt: P267
"C07AB12"
wdt: P274
"C₂₂H₂₅F₂NO₄"
wdt: P279
chemical compound
wdt: P2868
vasodilator agent
adrenergic beta-1 receptor agonists
antihypertensive drug
beta blocker
wdt: P2877
"19863"
wdt: P31
group of stereoisomers
wdt: P3117
"DTXSID9040556"
wdt: P3345
"31555"
wdt: P3417
"Nebivolol"
wdt: P3489
US pregnancy category C
wdt: P366
medication
wdt: P373
"Nebivolol"
wdt: P4250
5.0^^xsd:decimal
wdt: P486
"D000068577"
wdt: P592
"CHEMBL434394"
wdt: P595
"7246"
wdt: P6366
"2777537511"
wdt: P646
"/m/0dmbws"
wdt: P652
"030Y90569U"
wdt: P661
"64421"
wdt: P662
"71301"
wdt: P665
"D05127"
wdt: P672
"D02.033.100.291.491"
"D02.092.063.291.503"
"D03.383.663.283.755"
"D03.633.100.150.755"
wdt: P683
"64019"
wdt: P715
"DB04861"
wdt: P769
sildenafil
alfuzosin
terazosin
dronedarone
amiodarone
verapamil
rivastigmine
clonidine
methyldopa
tamsulosin
doxazosin
moxonidine
digoxin
diltiazem
disopyramide
fingolimod
prazosin
crizotinib
(RS)-propafenone
(E/Z)-doxepin
wdt: P7830
"Nebivolol"
wdt: P8026
LiverTox toxicity likelihood category E
wdt: P8494
"DTXCID7020556"
wdt: P9272
"55863"